Get the Stockscreener App
1.32
1.49%
-0.02
After Hours:
1.29
-0.03
-2.27%
Avenue Therapeutics Inc Stock (ATXI) Latest News
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Trajan Group Director Increases Stake Through Options - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
How Are Things Looking For Zeta Global Holdings Corp (NYSE: ZETA) For The Short Term? - Stocks Register
Avenue Therapeutics stock hits 52-week low at $1.5 amid challenges - Investing.com
Park Avenue Securities LLC Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Park Avenue Securities LLC Buys Shares of 1,684 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Assenagon Asset Management S.A. Sells 65,316 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Wall Street-Heavily Traded - WDRB
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Healthcare Triangle Faces Potential Delisting, Plans Annual Meeting - MSN
Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Park Avenue Securities LLC - Defense World
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Hennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL) - Defense World
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
AVTX (Avalo Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - Barchart
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Avadel Pharmaceuticals (NASDAQ:AVDL) Hits New 1-Year Low After Analyst Downgrade - Defense World
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month Low After Analyst Downgrade - Defense World
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Alvotech (NASDAQ:ALVO) - Defense World
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
State Street Corp Sells 47,600 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) - Defense World
Jane Street Group LLC Has $681,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
State Street Corp Grows Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Postoperative Pain Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million - Business Wire
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
Janux Therapeutics Announces Proposed Public Offering - Business Wire
APLT (Applied Therapeutics) Enterprise Value : $139.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Avenue Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
APLT (Applied Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion - The Wall Street Journal
Third trial failure is end-of-the-road for Sage's neurological drug - The Business Journals
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):